Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Shitiz Sriwastava to Multiple Sclerosis

This is a "connection" page, showing publications Shitiz Sriwastava has written about Multiple Sclerosis.

 
Connection Strength
  
 
 
7.008
  
  1. Tolaymat S, Sharma K, Kagzi Y, Sriwastava S. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Mult Scler Relat Disord. 2023 Jul; 75:104763.
    View in: PubMed
    Score: 0.769
  2. Sharma K, Tolaymat S, Yu H, Elkhooly M, Jaiswal S, Jena A, Kakara M, Sriwastava S. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review. J Neurol Sci. 2022 12 15; 443:120459.
    View in: PubMed
    Score: 0.738
  3. Peterson S, Jalil A, Beard K, Kakara M, Sriwastava S. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review. Mult Scler Relat Disord. 2022 Dec; 68:104125.
    View in: PubMed
    Score: 0.732
  4. Feizi P, Sharma K, Pasham SR, Nirwan L, Joseph J, Jaiswal S, Sriwastava S. Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review. J Neuroimmunol. 2022 10 15; 371:577939.
    View in: PubMed
    Score: 0.728
  5. Sharma K, Chaudhary D, Beard K, Srivastava S, Khalid SH, Sriwastava S. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients. Mult Scler Relat Disord. 2022 Mar; 59:103675.
    View in: PubMed
    Score: 0.704
  6. Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, Khalid SH, Lisak RP. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature. J Neurol. 2022 Mar; 269(3):1678-1687.
    View in: PubMed
    Score: 0.694
  7. Beard K, Sriwastava S. Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis. J Neurol Sci. 2021 Nov 15; 430:120034.
    View in: PubMed
    Score: 0.690
  8. Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S, Saber H, Tripathi R, Sheikh Z, Peterson S, Gwinn R, Bernitsas E. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021 11 15; 360:577721.
    View in: PubMed
    Score: 0.685
  9. Podury S, Khan E, Tandon M, Jaiswal S, Sriwastava S. Evolution of our understanding of MS-COVID-19 interactions and concerns for vaccination. J Clin Neurosci. 2021 Aug; 90:132-134.
    View in: PubMed
    Score: 0.671
  10. Sriwastava S, Yarraguntla K, Zutshi D, Basha MM, Bernitsas E, Marawar R. Relevance of cerebrospinal fluid findings in patients with multiple sclerosis and seizures. J Neurol Sci. 2019 Nov 15; 406:116482.
    View in: PubMed
    Score: 0.596
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.